TransMedics Group Inc (TMDX) shares recently surpassed the average analyst 12-month target price of $63.60, trading at $64.49 per share. This price movement raises questions about potential analyst reactions, which may include downgrading the stock or adjusting target prices higher based on the company’s fundamental developments.
Out of five analysts covering TransMedics, targets vary widely—ranging from a low of $55.00 to a high of $70.00—with a standard deviation of $5.639. Current ratings reflect three strong buy recommendations and one hold, averaging 1.5 on a scale where 1 is a strong buy and 5 is a strong sell.
This data suggests a consensus among analysts that, while there is optimism regarding TMDX, investors should carefully assess whether the recent price increase indicates further growth potential or if the stock may be overvalued at this point.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
